Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +35

Boston Scientific Corporation $BSX Shares Acquired by AIA Group Ltd

AI-generated analysis

πŸ“ˆ AIA Group Ltd increased its stake in Boston Scientific by 18.2% to 186,665 shares valued at $11.7 million during the first quarter.

🏦 Multiple institutional investors including FWL Investment Management and Bangor Savings Bank established or significantly increased their positions in Q2 and Q4.

πŸ“Š The company reported Q1 earnings of $0.80 EPS, beating analyst estimates of $0.79 on revenue of $5.20 billion.

πŸš€ Revenue grew 11.6% year-over-year to $5.20 billion, demonstrating strong top-line growth in the medical device sector.

πŸ’° The board authorized a new $5 billion share repurchase program, allowing the purchase of up to 6.4% of outstanding shares.

🎯 Analyst consensus rating is 'Moderate Buy' with an average price target of $79.84, though some firms lowered targets recently.

πŸ“‰ Mizuho cut its price target from $90 to $70 while maintaining an 'outperform' rating on the stock.

πŸ“‰ Jefferies and Bank of America also lowered their price targets to $67 and $68 respectively, though both maintain buy ratings.

πŸ’Ό Insiders purchased 9,800 shares valued at $554,012 in the last quarter, with directors Habiger and Pegus buying directly.

πŸ“ˆ The stock trades at a PEG ratio of 0.84 and a market cap of $65.33 billion with a beta of 0.58.

Bullish Signals
  • Boston Scientific beat Q1 earnings estimates with $0.80 EPS versus the consensus of $0.79, indicating operational strength.
  • Revenue increased 11.6% year-over-year to $5.20 billion, showing robust demand for the company's medical devices.
  • The board authorized a $5 billion share repurchase program, signaling management confidence that the stock is undervalued.
  • Analysts maintain a 'Moderate Buy' consensus rating with an average price target of $79.84, suggesting upside potential.
  • Insiders purchased 9,800 shares worth $554,012 in the last quarter, demonstrating internal confidence in the company's future.
  • The company maintains a healthy balance sheet with a current ratio of 1.90 and a debt-to-equity ratio of only 0.42.
Risk Factors
  • Several major analysts recently lowered their price targets, with Mizuho cutting from $90 to $70 and Jefferies from $100 to $67.
  • The stock is trading below its 50-day moving average of $48.18 and significantly below its 200-day moving average of $65.87.
Full Analysis
Boston Scientific Corporation (NYSE: BSX) saw increased institutional interest in the first quarter of 2026, with AIA Group Ltd growing its holdings by 18.2% to own 186,665 shares valued at $11.7 million. Several other institutions, including FWL Investment Management and Bangor Savings Bank, also established or increased their positions during the quarter, while hedge funds and institutional investors collectively hold 89.07% of the company's stock. Analyst sentiment remains mixed but generally positive regarding the company's valuation and future prospects. Major firms like Evercore, Mizuho, Jefferies, Bank of America, and BTIG have issued buy or outperform ratings with target prices ranging from $65 to $100. The consensus rating is a 'Moderate Buy' with an average price target of $79.84, though recent downgrades from higher targets suggest some caution among analysts. Financially, Boston Scientific reported strong performance in the quarter ended April 22nd, beating earnings estimates with $0.80 EPS and revenue of $5.20 billion, an 11.6% year-over-year increase. The company has set guidance for Q2 2026 EPS between $0.82 and $0.84 and full-year 2026 EPS between $3.34 and $3.41. Additionally, the board authorized a new $5 billion share repurchase program, signaling confidence in the stock's undervaluation. The company maintains a robust balance sheet with a market cap of $65.33 billion, a PEG ratio of 0.84, and healthy liquidity ratios. Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific focuses on less-invasive medical procedures for cardiovascular, digestive, urologic, pulmonary, and chronic pain conditions. Recent insider activity includes directors purchasing shares worth over $225,000 combined, further supporting the bullish outlook.